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In Brief
Inflammatory resolution was believed to
lead affected tissues back to
homeostasis. Newson et al. now find that
resolution triggers a prolonged phase of
localized immune suppression called
‘‘adapted homeostasis.’’ This phase is
mediated by macrophage-derived
prostaglandin E2 derived from COX-1/
mPGES1 and is crucial in preventing the
development of autoimmunity.
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Acute inflammation is characterized by granulocyte
infiltration followed by efferocytosing mononuclear
phagocytes, which pave the way for inflammatory
resolution. Until now, it was believed that resolu-
tion then leads back to homeostasis, the physiolog-
ical state tissues experience before inflammation
occurred. However, we discovered that resolution
triggered a prolonged phase of immune suppression
mediated by prostanoids. Specifically, once inflam-
mationwas switched off, natural killer cells, secreting
interferon g (IFNg), infiltrated the post-inflamed site.
IFNg upregulated microsomal prostaglandin E
synthase-1 (mPGES-1) alongside cyclo-oxygenase
(COX-1) within macrophage populations, resulting
in sustained prostaglandin (PG)E2 biosynthesis.
Whereas PGE2 suppressed local innate immunity to
bacterial infection, it also inhibited lymphocyte func-
tion and generated myeloid-derived suppressor
cells, the net effect of which was impaired uptake/
presentation of exogenous antigens. Therefore, we
have defined a sequence of post-resolution events
that dampens the propensity to develop autoimmune
responses to endogenous antigens at the cost of
local tissue infection.INTRODUCTION
Acute inflammation is a protective reaction of the microcircula-
tion initiated after infection and/or injury with the aim of elimi-
nating the inciting stimulus while promoting tissue repair and
healing (Lawrence et al., 2002; Nathan, 2002). Once the injurious
agent has been eliminated, a well-described sequence of events
called resolution ensues. These include pathogen clearance (Se-
gal and Peters, 1976), deactivation of pro-inflammatory signaling3162 Cell Reports 20, 3162–3175, September 26, 2017 ª 2017 The A
This is an open access article under the CC BY license (http://creativepathways (Stoecklin and Anderson, 2006), catabolism of cyto-
kines and chemokines (Jamieson et al., 2005), as well as
inhibition of granulocyte recruitment (Rajakariar et al., 2007).
Thereafter, the infiltrated granulocytes die by apoptosis and
are cleared by tissue-resident macrophages (Savill et al.,
1989). This entire process is relatively rapid, occurring within
3–5 days.
Upon successful resolution, there is the view that the inflamed
tissue reverts to the cellular and biochemical state it experienced
before infection/injury. However, there is increasing evidence
that resolution is not the end of innate immune-mediated re-
sponses to infection but that cellular and biochemical events
triggered by the resolution cascade influence subsequent adap-
tive immune responses (Leo´n et al., 2007; Nakano et al., 2009;
Newson et al., 2014; Wakim and Bevan, 2011). There is also
the emerging view that some infections cause ‘‘immunological
scarring’’ such that, despite effective clearance of the inciting
stimulus, rather than reverting to homeostatic normality, chronic
inflammation develops (Fonseca et al., 2015; Kuperman et al.,
2002). Taken together, these investigations suggest that resolu-
tion, as we currently understand it, is not the end of innate
immune-mediated responses to infection. Instead, once the car-
dinal signs of inflammation have abated, there is a great deal of
immunological activity occurring at the sub-clinical level, at the
site of inflammation, which dictates the long-term physiological
fate of tissues post-injury.
In support of this emerging concept, we found that, following
resolution of acute peritonitis, there was the sustained infiltration
of myeloid and lymphoid cells into the peritoneum that persisted
for months (Newson et al., 2014). We hypothesized that this
post-resolution infiltrate bridged the gap between innate and
adaptive immunity as depleting myeloid cells, for instance, dur-
ing this phase blunted lymph node expansion. Moreover, a
population of these infiltrated myeloid cells was retained in the
peritoneum long term and dictated the severity and longevity
of subsequent innate immune-mediated responses to second-
ary inflammatory stimuli (Newson et al., 2014; Yona et al.,
2013). Following on from this, we have now observed a
prolonged phase of prostanoid biosynthesis, namely PGE2,uthors.
commons.org/licenses/by/4.0/).
occurring within a few days of acute inflammation resolving. In
our attempts to understand what triggered PGE2 and decipher
its role in post-resolution biology, we found robust cyclo-oxy-
genase (COX-1)/PGES-1 expression in myeloid cells that was
triggered by interferon g (IFNg). It transpires that post-resolution
PGE2 is potently immune suppressive during this phase, with a
role in maintaining immune tolerance, but at the cost of
increased susceptibility to secondary infection.
RESULTS
IFNg-Induced IP-10/CXCL10 Triggers Post-resolution
Monocyte Infiltration
Resolution of acute inflammation in response to 0.1mg zymosan
occurs within 72–96 hr (Newson et al., 2014). Starting at day
three post-zymosan, and coincident with the end of resolution,
we noted the infiltration of natural killer (NK) cells peaking in num-
ber at days 9–14 and declining thereafter (Figure 1A); an equiva-
lent trend in this model was also seen with CD4 and CD8 T cells
(Newson et al., 2014). Mirroring NK cells, as well as T cells
(Newson et al., 2014), was an increase in cell-free inflammatory
exudate IFNg as well as monokine induced by gamma IFN
(MIG/CXCL9) and IFNg-induced protein 10 (IP-10/CXCL10) (Fig-
ures 1B–1D, respectively), with IFN-g being secreted by NK cells
as well as CD4 and CD8 T cells (Figures 1E and 1F). Given the
relative paucity of the classic monocyte chemoattractant
MCP-1 during this post-resolution phase (Figure 1G), we ques-
tioned whether IP-10, which is also a monocyte chemoattractant
(Taub et al., 1993), was responsible for post-resolution mono-
cyte accumulation in the peritoneum.
We injected zymosan into MIIG (macrophages insensitive to
IFNg) mice. These mice express a CD68-restricted dominant-
negative IFNg receptor that renders CD68+ macrophages insen-
sitive to IFNg (Lykens et al., 2010). We found substantially
reduced numbers of monocytes at day 14 in these animals
compared to wild-type controls (Figure 1H). To prove that the
infiltration of monocytes was caused by IP-10, we injected
wild-type mice bearing 0.1-mg-zymosan-induced peritonitis
with blocking antibodies to IP-10, MIG, or MCP-1. It transpires
that blocking only IP-10 reduced monocyte numbers during
post-resolution (representative data at day 14; Figure 1I). There-
fore, the infiltration of monocytes into post-resolving tissue is
caused by IP-10, most likely triggered by T-cell- and NK-cell-
derived IFNg.
Elevated and Sustained Post-resolution Prostanoid
Biosynthesis
Liquid chromatography-tandem mass spectrometry (LC-MS/
MS) analysis of cell-free inflammatory exudates revealed a
peak in PGE2 at day 14 post-0.1 mg zymosan being four times
higher than levels seen within the first few hours of inflammatory
onset (Figure 2A). A similar profile was seen with thromboxane
(Tx)B2 and prostacyclin (PGI2; measured as 6-keto PGF1a), but
not lipoxygenase or cytochrome p450 metabolites (Figure S1).
Western blotting analysis of total cells from the peritoneum
showed that COX-1 was expressed in cells of the naive cavity,
with levels declining during acute inflammation (4 hr) but rising
again fromday 3 (Figure 2B). In contrast, COX-2was absent fromthe naive peritoneum, transiently increased during early onset
(4 hr) and disappeared thereafter. Alongside changes in COX-1
expression were increases in both microsomal prostaglandin E
synthase-1 (mPGES-1) and -2 isoforms to levels persistently
higher than those seen in the naive cavity (Figure 2B; densitom-
etry values are shown in Figure S2A). These data suggest that
post-resolution increases in levels of PGE2 were not derived
from COX-2, as might be expected, but from COX-1 coupled
with mPGES isoforms.
Analysis of monocytes and macrophages up to day 28 re-
vealed at least three populations, namely Ly6Chi/F4-80 and
Ly6Clo/F4-80 monocytes as well as F4-80hi/CD11b+/MHC-IIhi
macrophages (data for day 14 are shown in Figure 2C). Further
analysis of the F4-80hi/CD11b+/MHC-IIhi macrophage popula-
tion using PKHred cell-tracking experiments revealed that
approximately 80% comprised macrophages that were resident
to the naive cavity (before zymosan injection), with the remaining
cells being monocyte derived (Figure 2D). Fluorescence-acti-
vated cell sorting (FACS) these respective populations followed
by quantitative real-time PCR traced the expression of COXs
and their downstream synthases to both tissue-resident as
well as infiltrating monocyte-derived macrophages (Figure 2E).
Given these expression profiles, it would appear that COX-1
and inducible mPGES-1 are the predominate source of post-res-
olution PGE2 expressed within myeloid cells; their expression at
RNA level was not detectable in lymphoid cells at this time point
(data not included).
Post-resolution EP Receptor Expression
It transpires that PGE2 receptor (EP)1 was not detectable on total
cells at the protein level (data not shown) whereas EP2–4 were
found throughout inflammation, resolution, and post-resolution
phases (Figure 3A; densitometry values are shown in Fig-
ure S2B). We next FACS sorted T and B cell populations from
the naive or post-resolution cavity as well as various mononu-
clear phagocytes (monocytes, monocyte-derivedmacrophages,
as well as tissue-resident macrophages) to determine cellular
expression of EP receptors. At the message level, EP2 and
EP4 were the most abundantly expressed by resident macro-
phages as well as monocyte-derived macrophages (Figure 3B);
T and B cells also expressed these receptors (Figure 3C). Data
from experiments in Figures 6A and 6B reveal EP4 to be most
functionally important on lymphocytes.
Collectively, these data reveal an unprecedented increase and
persistent temporal profile of prostanoid synthesis after inflam-
mation has resolved, driven by COX-1/mPGES with receptors
for these lipids expressed on cells of the post-inflamed cavity.
IFNg Drives Inducible mPGES-1 Expression
Given that the profile of IFNg in this model preceded that of PGE2
and that IFNg has been shown to trigger mPGES in colonic
epithelial cells (Wright et al., 2004), we investigated whether
IFNg was responsible for post-resolution prostanoid synthesis.
Incubating peritoneal macrophages with this cytokine (as well
as IP-10 and MIG at concentration found in the cavity at day 9)
resulted in an increase in mPGES-1 with no effect seen on
mPGES-2 levels (Figures 4A and 4B). Taking this further, we in-
jected zymosan into MIIG mice and, at day 14, FACS sortedCell Reports 20, 3162–3175, September 26, 2017 3163
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Figure 1. IFNg-Induced IP-10/CXCL10 Triggers Post-resolution Monocyte Infiltration
Wild-type mice had 0.1 mg zymosan injected into their peritoneal cavity with the cellular infiltrate analyzed by polychromatic flow cytometry starting from when
inflammation typically resolves in this model.
(A–D and G) Data show the accumulation of (A) NK cells followed by cell-free inflammatory exudates levels of (B) IFNg, (C) MIG, (D) IP-10, and (G) MCP-1.
(E and F) The key post-resolution cell types expressing IFN (E), and the intracellular staining for IFNg in these cells at days 9/14 after zymosan injection (F).
(H and I) Panels in (H) show the numbers of monocytes in MIIG mice (animals whose macrophages are insensitive to IFNg) at day 14 after zymosan, whereas (I)
confirms that IP-10 only is responsible for the infiltration of post-resolution monocytes in this model. *p% 0.05; **p% 0.01.
Data are expressed as mean ± SEM; n = 5 mice/group.
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Figure 2. Lipidomic Profiling of Inflamed and Post-resolved Tissues
(A) Peritoneal cell-free inflammatory exudates from mice that received 0.1 mg zymosan were analyzed by LC-MS/MS at indicated time points.
(B) Total peritoneal cells were subjected to western blotting to determine the temporal expression of the prostanoid-generating enzyme cascade.
(C) The profile of mononuclear phagocytes in the naive and post-inflamed cavity.
(legend continued on next page)
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Figure 3. Post-resolution EP Receptor
Expression
(A) Total peritoneal cells were subjected to western
blotting to determine the temporal expression of
prostanoid receptors.
(B and C) In addition to (B) monocyte/macrophage
populations, the post-resolution infiltration of (C)
CD4+, CD8+, and CD19+ lymphocytes were FACS
sorted to determine EP expression levels on
individual post-resolution myeloid and lymphoid
populations.
Data are presented as mean ± SEM; n = 6 mice per
group.post-resolution macrophage populations and subjected them to
qPCR, revealing a substantial decrease in mPGES-1, but not
mPGES-2 (Figures 4C and 4D). We also found that PGE2, when
incubated with post-resolution T cells, inhibited their secretion
of IFNg in an EP4-dependentmanner (Figure 4E). It was therefore
not surprising to see an increase in IFNg aswell asMIG and IP-10
at day 21 in mice treated with an EP4 receptor antagonist from
days 6 to 21 post-zymosan (Figures 4F–4H). These data show
that type II IFN triggers mPGES-1 expression and is responsible
for post-resolution prostanoid biosynthesis, with PGE2 acting as
a negative feedback inhibitor of IFNg synthesis.(D) The relative proportions of tissue-resident macrophages, which were labeled positively with PkH-PCLr
infiltrating monocyte-derived macrophages, which are cell tracker negative.
(E) FACS was used to separate tissue-resident macrophages (TR-Mfnaive), tissue-resident macrophages tha
Ly6chi/lo monocytes, and infiltrating monocyte-derived macrophages (mo-Mf) to determine cell expression
Data are expressed as mean ± SEM; n = 5 mice/group.
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Innate Immune Suppression
As PGE2 is a potent suppressor of innate
immunity (O’Brien et al., 2014; Serezani
et al., 2007), we injected S. pneumoniae
21 days after 0.1 mg zymosan and noted
that these mice became noticeably sicker
compared to naive controls that received
an equivalent amount of bacteria, with
their degree of clinical illness becoming
progressively worse up to 72 hr, when
these mice had to be euthanized. Impor-
tantly, inhibiting PGE2 synthesis or antag-
onizing its EP4 receptor reversed animal
sickness and resulted in greater clear-
ance of bacteria (Figures 5A and 5B,
respectively).
Post-resolution PGE2 Inhibits
Adaptive Immunity
In addition to innate immunity, PGE2 also
has potent modulatory effects on adap-
tive immunity (Kalinski, 2012). Coincident
with the second peak in PGE2 at day 14
in this 0.1 mg zymosan model was a
reduction in numbers of memory T and
B cells, with their contraction due, at leastin part, to programmed cell death, with apoptotic bodies being
cleared by tissue-resident macrophages (Figure S3) in line with
that reported previously (Newson et al., 2014; Uderhardt et al.,
2012).
Next, we found that PGE2 inhibited the ex vivo proliferation of T
and B cells sorted from the peritoneum 14 days post-zymosan in
an EP4-dependent manner (Figures 6A and 6B). Accordingly,
dosing animals from day 6 to day 21 post-zymosan with the
selective EP4 receptor antagonist MF-498 resulted in an in-
crease in numbers of peritoneal CD3+ T cells (Figure 6C); equiv-
alent data were obtained with the non-selective COX inhibitored when injected into the naive peritoneum versus
t experience inflammation (TR-Mfinflam.), infiltrated
of COXs and their downstream synthase.
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Figure 4. IFNg Triggers Post-resolution
mPGES-1 Expression
(A and B) The effects of IFNg as well as factors it
triggers, including MIG and IP-10 (used at levels
found at day 9 in the peritoneum), on macrophage
expression of COX and its downstream synthase
isoform expression (A), and (B) shows quantifica-
tion for mPGES-1.
(C and D) Zymosan was injected into macrophages
insensitive to IFNg (MIIG) mice, from which post-
resolution macrophage populations were FACS
sorted followed by qPCR to determine (C)
mPGES-1 and (D) mPGES-2 expression levels.
(E–H) T cells were isolated from the peritoneum at
day 14 post-zymosan and incubated ex vivo with
PGE2 (E), while the effects of an EP4 agonist on
cell-free exudate levels of IFNg (F), MIG (G), and
IP-10 (H) was determined at day 21.
*p % 0.05; **p % 0.01. Data are expressed as
mean ± SEM; n = 5 mice/group.naproxen (Figure S4). Blocking EP4 also skewed CD4+/CD44+/
CD62L memory T cells toward a Th1 phenotype based upon
an increased release of IFNg from these cells (Figure 6D).
Another important observation following the inhibition of post-
resolution PGE2 was a decrease in numbers of myeloid-derived
suppressor cells (Figure 6E), coincident with an increase in peri-
toneal dendritic cell numbers (Figure 6F), a differential effect that
is well-described in the literature (Obermajer and Kalinski, 2012;
Obermajer et al., 2011). The phenotype and suppressive function
of post-resolution myeloid-derived suppressor cells in panel C of
Figure 6E were identified as reported previously (Newson et al.,
2014).
From these data, we predict that PGE2 is highly immune
suppressive during the post-resolution phase of acute inflamma-
tory responses. To test this hypothesis, we injected methylatedCell ReportsBSA into the cavity of mice bearing a
0.1-mg-zymosan-induced peritonitis at
day 14 and found that a very weak
immune response was raised to this anti-
gen compared to when mBSA was in-
jected into naive mice; this immune sup-
pression was rescued by COX inhibition
(Figure 6G).
mPGES-1/PGE2 Is Absent in
Inflammation Triggered by 10 mg
Zymosan
Injecting higher levels of the same stim-
ulus (10 mg zymosan intraperitoneally
[i.p.]) caused a pronounced local granulo-
cytic infiltrate and systemic cytokine
storm (Newson et al., 2014). Nonetheless,
this inflammatory response also resolved
such that, within days, the composition
of the peritoneum in these mice was
similar to that of mice that received
0.1 mg zymosan in terms of neutrophiland pro-inflammatory cytokine profiles, classical determinants
of resolution (Newson et al., 2014). Indeed, in response to
10 mg zymosan, monocytes and macrophages were also
detected in the cavity up to day 21 with proportionally more
Ly6Clo/F4-80 monocytes observed (Figure 7A) compared to
inflammation triggered by 0.1 mg zymosan (see Figures 2C
and 2D; Newson et al., 2014). Importantly, of the F4-80hi/
CD11b+/MHC-IIhi mature macrophage populations, the majority
were derived from monocytes, with tissue-resident macro-
phages representing on average 5% of the mononuclear
phagocyte population (Figure 7B).
In addition, both IFNg and IP-10 were undetectable
throughout the response to 10 mg zymosan; instead, monocyte
chemotactic protein-1 (CCL2; Figure 7C) was followed by the
infiltration of the monocyte-derived macrophages bearing a20, 3162–3175, September 26, 2017 3167
AB
Figure 5. Post-resolution Tissues Are in a State of PGE2-Mediated
Innate Immune Suppression
Live bacteria (St. pneumonia) were injected into either naive mice or mice
bearing a 0.1-mg-zymosan-induced peritonitis at day 21. Separate groups of
zymosan-injected mice were dosed from day 6 post-zymosan injection with
either MF-498 (EP4 antagonist) or naproxen for two weeks.
(A) Howmice over time became progressively sick following bacteria. This was
assessed using a ‘‘murine sickness score,’’ which was developed in associ-
ation with the UCL animal welfare group and veterinary surgeon; see Experi-
mental Procedures.
(B) The number of surviving bacteria in the blood of these animals. *p% 0.05;
**p% 0.01.
Data are expressed as mean ± SEM; n = 6 mice/group.largely pro-inflammatory phenotype in comparison to equivalent
populations triggered by 0.1 mg zymosan (Figure 7D). In addi-
tion, the relatively few tissue-resident macrophages recovered
from the 10 mg zymosan model expressed less TIM4, ALOX15,
and transforming growth factor b1 (TGF-b1) (markers of effero-
cytosis) compared to equivalent counterparts recovered from3168 Cell Reports 20, 3162–3175, September 26, 20170.1 mg zymosan (Figure 7D). The lack of these dedicated effero-
cytosing phagocytes in the 10mgmodel was associatedwith the
accumulation of secondary apoptotic lymphocytes and granulo-
cytes bearing higher nucleic acid stain and annexin V labeling
(Figure 7E) compared to apoptosing lymphocytes seen following
0.1 mg zymosan (Figure S3). Not surprisingly, we detected anti-
bodies to double-stranded DNA (dsDNA) in the serum of these
animals rising from day 21 post-10 mg zymosan (Figure 7F).
Finally, exudates of mice injected with 10 mg zymosan revealed
no increased PGE2 levels or the expression of mPGES-1 (Fig-
ure 7G). We therefore investigated the impact of exogenously
adding a stable PGE2 analog to mice bearing a 10-mg-
zymosan-induced inflammation and found that dosing daily
from day 6 up to day 21 resulted in a reduction in serum anti-
bodies to dsDNA (Figure 7H).
DISCUSSION
Whereas the origins of chronic inflammatory or autoimmune dis-
eases remain unclear, multiple factors have been implicated,
including genetics, age, and environmental signals. Pathogens
are the main environmental factors postulated to drive autoim-
munity, with several hypotheses proposed to explain their mech-
anism of action, including molecular mimicry and bystander
activation (Fujinami et al., 1983, 2006; Woodland and Blackman,
1992). In addition, persistence of the infection arising from a
defective innate immune system (Dinauer, 1993; Morgenstern
et al., 1997; Segal, 1996) or failure to engage adaptive immunity
(Teijaro et al., 2013; Wilson et al., 2013) can also lead to chronic
inflammation and autoimmunity.
There is also evidence of immune dysfunction leading to
chronic disease occurring long after clearance of the infectious
stimulus. For instance, in a murine model of Sendai-induced
para-influenza, despite clearing the infection, mice progressed
to develop an asthma-like disease mediated by sustained activ-
ity of NK T cells driving macrophages to produce interleukin-13
(IL-13) (Kuperman et al., 2002). More recently, mice that received
a single inoculum of Yersinia pseudotuberculosis experienced
immune disruption in the gut weeks after bacterial clearance
(Fonseca et al., 2015). This disruption was characterized by
lymphatic leakage in the mesenteric adipose tissue that redir-
ected dendritic cells to the adipose compartment, thereby pre-
venting their proper accumulation in the mesenteric lymph
node. Consequently, mucosal immune functions, including toler-
ance and protective immunity, were persistently compromised.
Thus, even if the inciting stimulus is cleared, there is evidence
of local ‘‘immunological mal-adaption,’’ predisposing tissues to
chronic inflammation occurring months or years after the initial
exposure, at least in response to some infections. However,
the nature of this post-inflammation, immune mal-adaptation is
not clearly understood, and further research is warranted in
this area.
In this paper, we found that, following the resolution of acute
inflammation triggered by low-dose zymosan, there is a pro-
longed sequence of events at the cellular and molecular level
and occurring in a sub-clinical manner that may prevent the
development of some autoimmune diseases. One of the key
events in this process is the sustained synthesis of PGE2, which
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is derived frommacrophageCOX-1/mPGES and that is triggered
by IFNg. It transpires that this post-resolution phase of prosta-
noid biosynthesis creates a window of susceptibility to infection
on the one hand, while also impairing the host’s ability to
generate adaptive immune response to antigens on the other.
We interpret these data as an evolutionary trade-off, where the
threat of localized infection is more desirable than the specter
of developing autoimmunity to an endogenous antigen, such
as those generated by apoptotic cells during resolution, or
by citrullinated protein or collagen fragments following acute
inflammation.
The use of 10 mg zymosan in these studies has been some-
what serendipitous in that, whereas inflammation did eventually
resolve, at least as defined by polymorphonuclear neutrophil
(PMN) clearance and a return of total peritoneal cells to numbers
similar to the pre-inflamed cavity (Newson et al., 2014), the post-
resolution 10 mg zymosan peritoneum did not trigger NK cell
infiltration or elaborate IFNg/IP-10.Moreover, the numbers of tis-
sue-resident macrophages recovered from the cavity of these
animals was considerably less than that seen post-0.1 mg
zymosan whereas their phenotype was suggestive of a dimin-
ished capacity to efferocytose apoptotic cells. Instead, the
post-resolution 10 mg cavity saw the infiltration of monocyte-
derived macrophages bearing an M1-like phenotype not
expressing COX-1/mPGES or synthesizing prostanoids.We pro-
pose that the lack of efferocytosing tissue-resident macro-
phages resulted in the accumulation of secondary apoptotic
PMNs and lymphocytes, which, in the absence of immune-sup-
pressive PGE2, ultimately leads to the accumulation of anti-
bodies to dsDNA. Whereas these effects were inhibited when a
stable analog of PGE2 was dosed to 10 mg zymosan mice
from days 8 to 21, the precise mechanisms underlying these
findings are not known and beyond the scope of this paper but
most likely arise from the inhibition of memory T cell and/or
B cell proliferation or generation of suppressor myeloid or T cells.
Consequently, data presented here, as well as that published
by others (Fonseca et al., 2015; Kuperman et al., 2002), calls for a
clearer definition of inflammatory resolution. Until now, there was
the view that homeostasis is restored once acute inflammation
resolves (Serhan et al., 2007). In other words, inflamed tissues
revert to the state they experienced before infection/injury.
Arising from the above, it is clear that this is not the case. This
prompts us to put forward a revised definition of resolution.
The first occurs following transient inflammation and triggers a
sequence of events resulting in ‘‘resolution leading to adapted
homeostasis’’. This is the desired outcome of innate immune-
mediated responses to infection/injury, resulting in the mainte-Figure 6. Post-resolution PGE2 Inhibits Adaptive Immunity
(A and B) CD4+ (A) and CD19+ (B) cells were FACS sorted from the post-resolving c
to that found in the peritoneum at the same time (see Figure 2A), with/without EP
(C andD) The (C) impact of dosingmice with an EP4 receptor antagonist (MF-498 f
determined by intracellular IFNg.
(E and F) Inhibiting PGE2 synthesis (E) reduces numbers of myeloid-derived supp
peritoneum at day 14.
(G) Taking this further, methylated BSA (mBSA) was injected into the peritoneum o
this experiment were wild-type mice sensitized with complete Freund’s adjuvant
*p% 0.05; **p% 0.01; ***p% 0.001. Data are expressed as mean ± SEM; n = 6
3170 Cell Reports 20, 3162–3175, September 26, 2017nance of tolerance and prevention of chronic inflammation.
The second is where events leading to ‘‘adapted homeostasis’’
are dysregulated by the inflammatory stimulus and/or are inher-
ently absent/disrupted in the host. For this, we propose the term
‘‘resolution leading tomal-adapted homeostasis’’. This is the un-
desired outcome, which we suspect underpins the etiology of at
least some chronic inflammatory and autoimmune diseases.
The consensus is that IFNg is essentially pro-inflammatory in
nature. However, there is evidence to suggest that it may also
play a beneficial role in controlling autoimmunity and chronic in-
flammatory diseases. For instance, mice with a disrupted IFNg
gene are susceptible to experimental autoimmune encephalo-
myelitis (Ferber et al., 1996) whereas collagen-induced arthritis
is worsened in IFNg receptor-deficient mice (Vermeire et al.,
1997). In addition, IFNg knockout mice upregulate IL-1b and
accelerate collagen-induced arthritis in a mouse strain resistant
to developing arthritis when sensitized with collagen (Guedez
et al., 2001). Some of the mechanisms by which IFNg exerts its
protective effects in these settings have been revealed, including
the generation of immuno-regulatory indoleamine 2,3-dioxyge-
nase and the conversion of CD4+CD25 T cells to T-reg cells.
Such a paradoxical role is also apparent for type 1 IFNs. During
ongoing lymphocytic choriomeningitis virus infection, for
instance, levels of IFNa/b persist throughout the infectious
response. It emerges that, whereas early, acute production of
type 1 IFNs promotes virus clearance, chronic exposure to these
IFNs triggers immunosuppression via IL-10, programmed cell
death ligand 1, and indolamine signaling and causes T cell
apoptosis, collectively impairing the host’s ability to develop
specific immunity (Boasso et al., 2008; Gonza´lez-Navajas
et al., 2012).
Thus, whereas IFNg undoubtedly drives acute inflammation, it
also dampens multiple aspects of the adaptive immune system.
From our data, it appears that the signals inherent to ‘‘resolution
of acute inflammation leading to adapted homeostasis’’ trigger
the infiltration of no fewer than three cell types, including CD4,
CD8, and NK cells to ensure the release of IFNg, which, in
turn triggers PGE2 synthesis. The latter then carries out two
roles—(1) it impairs further IFNg synthesis and (2) maintains
post-inflammation tolerance. We believe that the negative
feedback effects of PGE2 on IFNgmay be key in beginning to un-
derstand the complex role of this Th-1 cytokine in the dynamic
continuum that is the immune response—a transient increase
lasting for no more than a week (days 6–14 post-0.1 mg
zymosan), during which we assume it exerts multiple (unknown)
effects on various aspects of post-resolution biology, culmi-
nating in COX1/mPGEs-1 expression. Whether PGE2 and otheravity (day 14) and incubated with increasing concentrations of PGE2 equivalent
receptor antagonists.
rom day 6 until day 21) on T cell numbers in situ as well as their (D) phenotype as
ressor cells (sub-panel C) while increasing numbers of (F) dendritic cells in the
r naive mice as well as those bearing a 0.1 mg zymosan at day 14; controls for
containing mBSA with recall assays carried out on T/B cells.
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(Figure 7 continued on next page)prostanoids are the eventual effector molecules of IFNg’s pro-
tective role in collagen-induced arthritis and experimental auto-
immune encephalomyelitis remains to be investigated.
PGE2 is erroneously thought of as purely pro-inflammatory,
largely, we suspect, due to its association with nonsteroidalanti-inflammatory drugs (NSAIDs) (Moncada and Vane, 1978).
Whereas the latter are certainly anti-inflammatory (Abramson
et al., 1985) and undoubtedly do inhibit COX enzyme activity
(Ferreira et al., 1971; Flower et al., 1972; Vane, 1971), NSAIDs
possess myriad other anti-inflammatory properties aside fromCell Reports 20, 3162–3175, September 26, 2017 3171
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Figure 7. Autoantibodies Generated by Inflammation Driven by 10 mg Zymosan Are Inhibited by PGE2
(A) Wild-type mice were injected with 10 mg zymosan and subjected to polychromatic flow cytometry at the indicated time points for the determination of cells of
the monocyte/macrophage lineage.
(B) Following the injection of cell-tracker dyes (PKH red) into the naive peritoneum, we were able to discern tissue-resident from infiltrating monocyte-derived
macrophages (mo-Mf).
(C andD) Levels of the (C) classicmonocyte chemoattractantMCP-1were determined in the peritoneal fluid, whereas at day 14 post-zymosan, (D) tissue-resident
from infiltrating monocyte-derived macrophages were FACS sorted for the determination of their phenotype by PCR.
(E–G) At this time point, profiles of (E) apoptotic lymphocytes and granulocytes are shown alongside (F) serum levels of antibodies to dsDNA occurring in the
absence of (G) peritoneal PGE2, effects that were reversed when (H) mice receiving 10 mg zymosan were dosed from days 6 to 21 with a stable PGE2 analog.
Data are expressed as mean ± SEM; n = 6 mice/group.COX inhibition (Abramson and Weissmann, 1989). With this in
mind, we wish to put the role of PGE2 in immunity into perspec-
tive. Unarguably, PGE2 does cause pain and edema. However, it
also suppresses bacterial phagocytosis (Aronoff et al., 2004,
2009; Medeiros et al., 2009) and NADPH-mediated bacterial
killing (Serezani et al., 2005, 2007) as well as directly inhibiting
T cell proliferation (Baker et al., 1981; Betz and Fox, 1991) while
driving myeloid-derived suppressor cell formation (Mao et al.,
2014; Obermajer and Kalinski, 2012; Sinha et al., 2007), in which3172 Cell Reports 20, 3162–3175, September 26, 2017case PGE2 exerts multiple modulatory effects on innate and
adaptive immunity with its predominant effect/smost likely being
context dependent. With respect to our current findings, we
report that, whereas PGE2 opens up a window of local infectious
opportunity, this is done in order to minimize the development of
autoimmune disease, a lesser of two evils, as it were.
The conventional wisdom is that COX-2 is required for robust
and substantially elevated prostanoid synthesis, such as that
made during inflammation, whereas COX-1 makes prostanoids
at comparatively lower levels for the purpose of maintaining
normal gut and renal physiology (Simmons et al., 2004). How-
ever, we found particularly high levels of prostanoids at day 14
derived from COX-1 with COX-2 being absent; in fact, these
levels were higher than we have ever noted in animal model of
inflammation. It transpires that these post-resolution prosta-
noids are most likely synthesized by IFNg-induced mPGES-1,
though a contribution from mPGES-2 cannot be ruled out. We
do not see this phase of prolonged PGE2 and indeed prostacy-
clin synthesis as being pathogenic, as animals in the post-reso-
lution phase do not exhibit signs of discomfort or pain, events
driven by PGE2 (Kawabata, 2011) and PGI2 (Schuh et al.,
2014). Indeed, it would be of great interest to understand the
endogenous mechanisms that counter-regulate the effects of
these nociceptive lipid mediators in the peritoneum at day 14
post-zymosan and speculate how these protective pathways
might become dysregulated during chronic pain.
In summary, we report on a sequence of events specific to res-
olution of acute inflammation, leading to ‘‘adapted homeostasis’’
that are essential for the maintenance of immune tolerance to
endogenous antigens. We propose that this COX-1/mPGES
axis is an internal checkpoint central to preventing the develop-
ment of diseases driven by autoimmunity, which may be dysre-
gulated in individuals with a propensity to developing chronic
inflammation or subverted by infectious stimuli known to cause
chronic inflammation.
EXPERIMENTAL PROCEDURES
Flow Cytometry
Flow cytometry and cell sorting were done on the LSR-Fortessa and FACSAria
(BD Biosciences), respectively. Cells were incubated in FACS buffer (5% heat
inactivated fetal bovine serum [FBS] [Life Technologies], 2 mM EDTA [Sigma])
in PBS (Life Technologies) with fluorescent-labeled antibodies. Data were
analyzed with Flow-Jo 10.2 software (Tree Star) using fluorescent minus one
controls for setting gates. Antibodies for mouse studies were obtained from
BD Biosciences (Ly6C, CD11b, NK1.1, and CD8), eBioscience (Ki67, F4/80,
Foxp3, and CD115), and BioLegend (Ly6G, CD3, CD19, CD4, CD44, CD62L,
CD11c, major histocompatibility complex [MHC]-II, IFN-g, tumor necrosis fac-
tor [TNF], IL-10, IL-6, immunoglobulin G1 [IgG1], and IgG2a). For intracellular
staining, 600,000 cells were incubated in DMEM containing penicillin/strepto-
mycin, 10% FBS, and 2 mM L-glutamine (all Life Technologies) with 10 mg/mL
brefeldin A (Sigma), 5 ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma),
and 500 ng/mL ionomycin (Cayman Chemical) or 1 mg/mL lipopolysaccharide
(LPS) (Sigma) for 4 hr. Cells were stained with extra cellular markers and then
washedand incubatedwith Fix/Perm (eBioscience) andwashedand incubated
with Permwash (eBioscience) and fluorescent-labeled antibodies (IFNg).
Cytokine Measurements
Cell-free exudates were measured for cytokines with a R&D Systems Luminex
screening assay according to the manufacturer’s instructions.
PCR
Sorted cell populations were subjected to RNA extraction using the RNeasy
micro-kit (QIAGEN) according to the manufacturer’s instructions. Contami-
nating DNA was removed by DNase I (QIAGEN) treatment. Real-time PCR
was performed after 500 ng of RNA was reverse transcribed. A total of 3 ng
cDNA was analyzed by quantitative real-time PCR (Applied Biosystems
7900HT) and quantified by power SYBR Green (Applied Biosystems) accord-
ing to the manufacturer’s instructions. For data analysis, the comparative
threshold cycle values for constitutively expressed cyclophilin were used to
normalize loading variations and are expressed as a.u.Animals, Drugs, and Cell-Tracking Studies
Male C57Bl6/J mice (aged 8–10 weeks) were maintained in accordance with
UK Home Office regulations (project license number P69E3D849; establish-
ment license number X7069SDD). Peritonitis was induced by injecting soni-
cated 0.1 or 10 mg/mouse zymosan A (Sigma) intraperitoneally; 40,000 col-
ony-forming units (CFU) Streptococcus pneumoniaeova323–339/mouse were
injected at the times indicated. Streptococcus pneumoniaeova323–339 was ob-
tained from Gerry Brown, University College London (UCL). PKH26-PCLred
(350 mL of 0.5 mM; Sigma) was injected intraperitoneally 2 hr prior to induction
of peritonitis. Naproxen was either given (10 mg/kg; Sigma) orally in gum trag-
acanth twice a day from day 6 to day 14 or 21 or 20 mg/kg in drinking water
from day 6 to day 21 or day 28. MF498 in gum tragacanth (30 mg/kg; Cayman
Chemical) was given orally from day 6 to day 14. Bacterial handling, growth,
and animal inoculation were carried out as previously described (Stables
et al., 2010).
Animal Sensitization Studies
Mice were injected with 0.1 mg zymosan intraperitoneally and dosed with
20 mg/kg naproxen in drinking water from day 6 to day 21 or 28. On day
14, mice were injected intraperitoneally with 10 mg/mL methylated BSA
(mBSA) (Sigma). Additionally, naive mice were injected with 10 mg/mL
mBSA in complete Freund’s adjuvant subcutaneously (Sigma) and left
for 10 days. Bone-marrow-derived dendritic cells (DCs) were generated
as previously described, and 60,000 per well were incubated overnight
with 100 ng/mL LPS and 20 ng/mL Met BSA. DCs were washed and incu-
bated with 300,000 lingual lymph node cells in RPMI (Life Technologies)
with 30 U/mL IL-2 (Miltenyi Biotec) for 4 days. Cells were stained for
FACS with CD11b, F480, CD11c, MHCII, CD19, CD3, CD4, CD8, and
Ki67.
Measurements of dsDNA
Blood was taken by cardiac puncture, the blood was left to clot, and the serum
stored at 80C until analysis. High binding plates were (Costar; Appleton
Woods) first coated with 20 mg/mL of poly-L-lysine (Sigma) and then
20 mg/mL calf thymus DNA (Sigma). Serum was diluted 1:100 with 1% BSA
(Sigma) in PBS for 1 hr at room temperature. Plates were washed and incu-
batedwith goat anti-mouse IgG-horseradish peroxidase (HRP) (Thermo Scien-
tific). Data are expressed as optical density.
Lipidomics
COX- and LOX-derived lipid mediators were extracted from cell-free inflam-
matory exudates as previously described (Massey and Nicolaou, 2013).
Briefly, samples were defrosted on ice and then diluted to 4 mL at a final con-
centration of 15% (v/v) methanol/water. Internal standards were added (20 ng
each of PGB2-d4, 12-HETE-d8, 8,9DHET-d11, and 8(9)EET-d11; Cayman
Chemical, Ann Arbor, USA). Semi-purification of samples was performed
using solid-phase extraction (C18-E cartridges; Phenomenex, Macclesfield,
UK), and lipid mediators were eluted using methyl formate. Analytes were
separated on a C18 column (Acquity UPLC BEH; 1.7 mm; 2.1 3 50 mm;
Waters, Wilmslow, UK) using ultraperformance liquid chromatography
(Acquity; Waters, Wilmslow, UK) coupled to a triple quadrupole mass spec-
trometer with electrospray ionization (Xevo TQ-S; Waters, Wilmslow, UK).
Analytes were quantified using multiple reaction monitoring and calibration
lines constructed using commercially available standards (Cayman Chemi-
cals, Ann Arbor, USA).
Cell Culture
Naive peritoneal washouts were spun down at 500 g for 5 min to separate cells
from inflammatory exudate. Cells were then resuspended in ACK lysis buffer
(Lonza) to remove red blood cells for 30 s, after which they were diluted with
FACS buffer and spun as above. Cells were resuspended in MACS buffer
and counted and incubated with anti-mouse CD19 beads (Miltenyi Biotec)
for 15 min. The labeled cells were washed and passed through an MS column
(Miltenyi Biotec). The flowthrough was plated out at 450,000 cells per well on a
24-well plate. Cells were left to adhere for 30 min, after which non-adherent
cells were washed off. Naive macrophages were incubated with 100 ng/mL
TNFa, 250 pg/mL IFNg, 300 pg/mL IP-10, and 300 pg/mL MIG (Peprotech)Cell Reports 20, 3162–3175, September 26, 2017 3173
for 24 hr. Cell supernatants were stored at 80C, and cells were stored
at 80C in RIPA buffer for analysis by western blot.
Western Blotting
Western blotting was carried out as previously described (Newson et al.,
2014). Briefly, cells from peritoneal washouts or ex vivo culture were lysed in
RIPA buffer with protease inhibitors (both Sigma) and the protein concentra-
tion determined by Bradford assay (Bio-Rad). Ten micrograms of protein
were separated by SDS-PAGE (National Diagnostics). Separated proteins
were transferred onto a polyvinylidene fluoride membrane (Immobilon; Milli-
pore) and incubated with COX-1, COX-2, mPGES-1, mPGE-2, EP1-4 (Cayman
Chemical), b-actin, and GAPDH (Sigma) overnight in block buffer (Tris-HCL,
1% Tween-20, 1% BSA [Sigma], and 5% nonfat milk [Marvel]). Blots were
washed and incubated with HRP-conjugated antibodies (Santa Cruz Biotech-
nology) for 1 hr at room temperature in blocking buffer. Specific proteins were
visualized by enhanced chemiluminescence (ECL) hyperfilm.
Murine Sickness Score
Mice injected with Streptococcus pneumoniae were monitored at the times
indicated in the results. Each mouse was scored for levels of sickness based
on the following scoring system. If a mouse showed signs of piloerection, slow
movement, and a hunched posture, then a score of 1 was given. If a mouse
displayed 2 of these parameters, then a score of 2 was given. Mice showing
all three of these clinical signs or pus in eyes were given a score of 3. Failure
to move was scored at 4, at which point the mice were killed.
Statistical Analysis
For comparisons between multiple groups, 1-way ANOVA with repeated mea-
sures was performed followed by Bonferroni post-test. Comparisons between
2 groupsweremade by 2-tailed (un)paired t test. Data are presented asmean±
SEM with numbers of animals used per experiment stipulated accordingly.
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